PPC
SUPN icon

Park Place Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Park Place Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-198
Closed -$6.75K – 925
2024
Q1 		$6.75K Hold
198
– – ﹤0.01% 705
2023
Q4 		$5.73K Hold
198
– – ﹤0.01% 707
2023
Q3 		$5.46K Hold
198
– – ﹤0.01% 844
2023
Q2 		$5.95K Hold
198
– – ﹤0.01% 843
2023
Q1 		$7.17K Hold
198
– – ﹤0.01% 813
2022
Q4 		$7K Buy
+198
New +$6.88K ﹤0.01% 819

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Park Place Capital's SUPN Position: Q2 2024 in Review

Park Place Capital sold out of Supernus Pharmaceuticals (SUPN) in Q2 2024, closing a stake of 198 shares — an estimated $6.75K sold.

Park Place Capital first reported a position in SUPN in Q4 2022 and held it in 6 quarters. The position peaked at $7.17K in Q1 2023. 244 funds tracked by Wall St. Rank hold SUPN as of Q2 2024.

  • Park Place Capital reported no remaining Supernus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Park Place Capital sold 198 Supernus Pharmaceuticals shares in Q2 2024, an estimated $6.75K.
  • Park Place Capital first reported a position in Supernus Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • Park Place Capital's Supernus Pharmaceuticals position peaked at $7.17K in Q1 2023.
  • 244 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2024.

Based on Park Place Capital's 13F filing for Q2 2024, filed 2 Jul 2024.